The Swiss Market Index recovered on Tuesday, closing 0.34% higher, amid a barrage of business surveys, company updates and economic data prints.
Switzerland's manufacturing PMI climbed to 57.1 in August from 53.2 in July, supported by an increase in production, order backlogs and purchasing activity, according to procure.ch and UBS data. The latest reading also marks the sixth straight month the index came in above the growth threshold of 50.
On the retail front, data from the Federal Statistical Office showed that seasonally adjusted retail sales in the country ticked up 0.1% month over month in real terms in July, following a revised 0.3% increase in June.
Zooming out to the euro area, the annual inflation rate accelerated to 3.3% in August from 2.9% in July, while the annual core inflation rate ticked down to 2.4% from 2.5%, Eurostat's flash data showed.
Over to corporates, Novartis (NOVN.SW) reported that its phase 3 Remodel-1/-2 trials for remibrutinib met their primary endpoint of "significantly" reducing annualized relapse rate in adult patients with relapsing multiple sclerosis, compared with teriflunomide, without liver safety issues. The oral Bruton's tyrosine kinase inhibitor also showed "clinically meaningful" reductions, against teriflunomide, in key secondary endpoints related to disability progression. The Swiss drugmaker's stock added 6.25% at closing.
"We forecast $3bn un-risk adjusted peak sales for remi, with upside potential based on exact progression data The positive remi MS data likely increases investor conviction in remi's potential as a [greater than] $10bn asset across indications (CSU, CINDU, MS, HS data 4Q26, MG PIII FY28, Food Allergy PIII started). An anchor, large asset supports growth profile through patent cliff," analysts at BofA Global Research said in a note. "We model a total $26bn MS market and see potential for BTKi's to replace most existing orals (c$7bn) due to better efficacy, and potential to compete in certain settings vs CD20s (c$15bn)."
UBS Group (UBSG.SW) acknowledged recommendations from the Swiss parliament's Economic Affairs and Taxation Committee of the upper chamber offering alternatives to the Federal Council's "extreme" banking regulation proposals, requiring the group's parent bank UBS AG to hold 50% common equity Tier 1 capital and up to 50% additional Tier 1 capital, up from the current 45% and 15%, respectively. However, the group warned that the recommendations would still lead to "a significant increase in costs" for the banking group.
Meanwhile, Swiss Finance Minister Karin Keller-Sutter criticized the committee's plan to soften the substantial new capital requirements to be imposed on UBS. At the end of trading, UBS shares declined 0.32%.